Susan Samson, MD, PhD, of the Mayo Clinic in Jacksonville, FL, talks about the latest long term data presented at ENDO 2021 testing oral octreotide in people with acromegaly.
In a 48-week open label extension of the CHIASMA OPTIMAL study, patients with acromegaly received oral octreotide capsules (half from the group getting the capsules and half from the group getting placebo from the original placebo-controlled trial). As Dr. Samson explains in this interview, patients in the open label extension continued to do well with the drug with no drop in efficacy.
The abstract from the study is available here.
Acromegaly is a rare endocrine disorder that develops when your body makes too much growth hormone, usually as a result of a pituitary tumor. When that tumor develops in adulthood, excess secretion of growth hormone can lead to a plethora of symptoms, including abnormal growth of extremities, skeletal changes, altered facial features, arthritis, carpal tunnel syndrome, enlargement of body organs, and various other symptoms.
To stay abreast of the latest developments from ENDO and other medical conferences, sign up for our specialty newsletters at checkrare.com/sign-up-for-our-newsletter/